Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.57 – $0.88
17% from low
No one on the platform currently holds LSB.
No tracked institution reports a position in LSB as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-10-04 | 1-for-10reverse |
No one on the platform has traded LSB yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $1.7B | +24.4% | $35.51 | $35.51–$35.51 | 0.0× | 1 |
| 2028 | $1.9B | +9.9% | $43.73 | $43.73–$43.73 | 0.0× | 1 |
| 2029 | $1.7B | -10.1% | $35.07 | $35.07–$35.07 | 0.0× | 1 |
| 2030 | $1.9B | +9.9% | $43.19 | $43.19–$43.19 | 0.0× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 4 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-04-18 | $-0.60 | $-1.20 | -100.0% |
| 2025-01-27 | $-0.80 | $-1.60 | -100.0% |
| 2024-09-24 | $-0.58 | $-1.34 | -131.0% |
| 2024-04-19 | $-0.09 | $-0.12 | -33.3% |
| $28M |
| — |
| GMTXGemini Therapeutics, Inc. | $1.35 | +0.00% | $25M | — |
| IVCInvacare Corporation | $0.66 | +0.00% | $25M | — |
Source: Financial Modeling Prep · peers by sector/industry
$LSB Brilliant piece that captures LSB's situation perfectly. So if you want to update your understanding of LSB or get to know LSB better, this is essential reading. https://beyondspx.com/quote/LSB/analysis/lakeshore-biopharma-unlocking-value-through-proprietary-pika-technology-and-strategic-market-expansion-lsb
View on StockTwits ↗$LSB 08:04 on Sep. 12 2025 LakeShore Biopharma Receives Nasdaq Non-Compliance Notice #tradeideas
View on StockTwits ↗LakeShore Biopharma Receives Revised Proposal To Acquire Company $LSB https://stocktwits.com/news/equity/markets/lakeshore-biopharma-receives-revised-proposal-to-acquire-company/chs6JRRRdmm
View on StockTwits ↗LakeShore Biopharma Just Got An Acquisition Proposal From Oceanpine Capital: More Details Inside $LSB https://stocktwits.com/news/equity/markets/lakeshore-biopharma-got-an-acquisition-proposal-from-oceanpine-capital/chsO9ANRdXT
View on StockTwits ↗$QNTM $IBO $ALUR $GLTO $LSB $QNTM is targeting 3 big markets: • MS repair • Hangover relief • Alcohol detox Debt-free, $10.3M in assets, funded through 2027. Which catalyst hits first — Phase 2 MS trial, Unbuzzd sales growth, or REKVRY trial results? https://analyticainvestor.beehiiv.com/p/quantum-biopharma-taking-brain-health-in-bold-new-directions-803d3cda283ced6d
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.